• E-64d at the Proteostasis Decision Point

  2026-08-22

  E-64d is a membrane-permeable cysteine protease inhibitor that helps separate calpain- and cathepsin-dependent phenotypes from autophagic or proteasomal degradation. This article translates a recent Arabidopsis autophagy study into practical assay decisions without treating E-64d as a nonspecific substitute for genetic pathway analysis.

• Betaine Hydrochloride for Translational Assays

  2026-08-22

  Betaine hydrochloride can be used as a deliberately controlled variable in enzyme, protease, cell culture, and molecular biology workflows—not merely as a soluble reagent. This guide connects practical assay design with the inflammation-focused esophageal cancer study of oridonin while clearly separating published findings from recommended validation experiments.

• BOP Reagent in Translational Prodrug Design

  2026-08-21

  A mechanistic and strategic guide to using BOP reagent in peptide and prodrug workflows, with a clear evidence bridge to carrier-free, ROS-responsive triterpene systems investigated for oral squamous cell carcinoma.

• DiscoveryProbe Bioactive Compound Library Plus for TSA

  2026-08-20

  Pair a broad, pre-dissolved small-molecule collection with thermal shift assay design to move from ligand discovery to pathway-level validation. The workflow combines bacterial sensor-protein biophysics, orthogonal binding confirmation, and cell-based follow-up for more defensible screening decisions.

• Novel Ziprasidone Impurity: Methods and Significance

  2026-08-20

  The reference study identified and structurally characterized methylene ziprasidone dimer, an unknown process-related impurity detected during ziprasidone hydrochloride scale-up. Its combined HPLC, HRMS, and multidimensional NMR workflow provides a practical model for investigating low-level impurities that may affect pharmaceutical quality assessment.

• APEX2 Enables Efficient TERT Expression in Stem Cells

  2026-08-19

  A 2024 preprint identifies APEX2 as a DNA repair enzyme required for efficient TERT expression and telomerase activity in human embryonic stem cells, with similar evidence in a melanoma cell line. Its RNA-seq and chromatin-binding results suggest that repair of damage-prone repetitive DNA within the TERT locus, rather than strong promoter occupancy, may connect APEX2 to gene regulation.

• Trelagliptin, RUNX2, and Osteoblast Differentiation

  2026-08-19

  The reference study identifies a previously underexplored effect of the DPP-4 inhibitor trelagliptin: promotion of osteoblastic differentiation and mineralization in MC3T3-E1 cells. Its data connect this phenotype to increased RUNX2 and AMPK signaling, offering a mechanistic rationale for further osteoporosis research while remaining limited to an in vitro model.

• Gly-Gly-Phe-Gly (GGFG) Workflow Guide

  2026-08-18

  Gly-Gly-Phe-Gly is a defined, glycine-rich peptide spacer for modular drug conjugation research, peptide engineering, and biomaterial construction. This practical guide covers dissolution, coupling design, analytical verification, assay selection, and troubleshooting without confusing linker performance with evidence from unrelated therapeutic studies.

• BOP Reagent for Peptide Prodrug Workflows

  2026-08-18

  Learn how BOP reagent supports carboxyl group activation, phenyl ester preparation, blocked amino acid derivatives, and amide bond formation in research-scale synthesis. The workflow also explains how this chemistry can be evaluated prospectively in triterpene-based prodrug programs inspired by recent oral squamous cell carcinoma research.

• Fumagillin Against Azumiobodo hoyamushi

  2026-08-17

  The reference study compared 20 antiprotozoal, antibiotic, antifungal, oxidizing, and halogen-based agents against Azumiobodo hoyamushi, identifying Fumagillin as moderately active in vitro. Its two-stage design also showed why parasite killing in culture must be separated from host-compatible disinfection: formalin and chlorine dioxide reduced parasite burdens in experimentally infected ascidians, whereas Fumagillin was not advanced to the in vivo phase.

• LTI6426 Enhances Panobinostat in Multiple Myeloma

  2026-08-17

  Robinson and colleagues report that the protein disulfide isomerase inhibitor LTI6426 markedly improves the anti-myeloma activity of low-dose panobinostat in cell and animal models, including proteasome inhibitor-resistant disease. Their results connect the combination to endoplasmic reticulum stress effectors ATF3, DDIT3/CHOP, and DNAJB1, providing a rationale for dose-sparing treatment design and candidate pharmacodynamic biomarker development.

• HOBt in Medicinal Chemistry: From Coupling to GRAs

  2026-08-16

  HOBt (1-Hydroxybenzotriazole) is more than a peptide coupling additive. This evidence-led case study shows how its amide-forming chemistry supported a modular glucagon receptor antagonist program and how researchers can separate synthetic success from assay-ready molecular quality.

• Proteinase K as a Protease Assay Control

  2026-08-15

  Proteinase K is more than a DNA-preparation reagent: it is a broad-spectrum serine protease that can strengthen assay controls and protein-removal workflows. This article connects its biochemical operating range with a SARS-CoV-2 protease screening study to show how selectivity, stability, and orthogonal controls improve experimental interpretation.

• Berberine–PPARγ Signaling in Atherosclerosis

  2026-08-14

  The 2025 study identifies an RXRα/PPARγ/NEDD4 axis through which berberine suppresses SASP-related inflammation in macrophage-derived foam cells and ApoE-deficient atherosclerotic mice. Its key contribution is linking nuclear-receptor activation to ubiquitination-mediated turnover of the GATA4/p62 complex, providing a mechanistic framework for targeting inflammaging within plaques.

• Refining In Vitro Metrics for Cancer Drug Responses

  2026-08-14

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability to separate growth inhibition from actual cell killing in cancer drug studies. Its central contribution is a more interpretable framework for analyzing response magnitude, composition, and timing, with practical implications for assay design and translational comparisons.

7840 records 1/523 page Next 12345 下5页 Last page